Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
St. Charles considers restrictions, tax on short-term rentals
St. Charles could impose new regulations and fees for AirBnbs, Vrbos and other short-term rentals currently... -
Campton Hills could annex 962 acres for 900-home development
In a departure from the contentious now-dead project of Settlements of LaFox’s more than 2,000 homes... -
García delivers 6th career walk-off hit as Sox drop fourth straight
Adolis García delivered his his sixth career walk-off hit with an RBI single with two out...